The P-III (KEYLYNK-006) study investigates Keytruda + CT (pemetrexed + carboplatin/cisplatin) followed by either Keytruda + maintenance Lynparza or Keytruda + maintenance CT (pemetrexed) as a 1L treatment of metastatic non-squamous NSCLC without EGFR, ALK or ROS1 genomic tumor aberrations
The study did not meet the dual 1EP of OS & PFS with Keytruda + CT followed by Keytruda + maintenance Lynparza. Full clinical evaluation is underway & will be shared with the scientific community
The safety profiles of Keytruda and Lynparza were consistent with their prior individual studies
Ref: Merck | Image: Merck
Related News:- Merck Reports Results from the P-III (KEYNOTE-A18) Study of Keytruda for the Treatment of Cervical Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
